ISRCTN81334858 https://doi.org/10.1186/ISRCTN81334858

Oral chemotherapy versus intravenous chemotherapy in limited or extensive small cell lung cancer

Submission date 01/07/2001	**Recruitment status** Stopped	[ ] Prospectively registered [ ] Protocol [ ] Statistical analysis plan [ ] Results [ ] Individual participant data [ ] Record updated in last year
Registration date 01/07/2001	**Overall study status** Stopped	
Last Edited 18/09/2017	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
LU309

Study information

Scientific Title
Oral chemotherapy versus intravenous chemotherapy in limited or extensive small cell lung cancer: a randomised controlled trial

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Not Specified

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Lung (small cell)

Interventions
1. Oral Regimen: Oral etoposide and cyclophosphamide given over 5 days every 3 weeks.
2. Intravenous Regimen: Intravenous combination of three or more drugs routinely used in the centre with the usual dose reduction. A standard alternative is adriamycin, cyclophosphamide and vincristine (VAC) repeated every 3 weeks.

Intervention Type
Other

Phase
Not Specified

Primary outcome measure

Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/01/1995

Completion date
31/12/2000

Reason abandoned (if study stopped)
Objectives no longer viable

Eligibility

Key inclusion criteria
1. Histologically or cytologically proven small cell lung cancer
2. No previous or concurrent malignancy
3. Fit to receive chemotherapy
4. No prior chemotherapy or radiotherapy
5. No biochemical or haematological abnormalities which would preclude chemotherapy

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
Not provided at time of registration

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/1995

Date of final enrolment
31/12/2000

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Cancer Research UK (CRUK) (UK)

Sponsor details
PO Box 123
Lincoln's Inn Fields
London
United Kingdom
WC2A 3PX
+44 (0)207 317 5186
kate.law@cancer.org.uk

Sponsor type
Charity

Website
http://www.cancer.org.uk

ROR
https://ror.org/054225q67

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK

Alternative Name(s)
CR_UK, Cancer Research UK - London, CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Interim results article	interim results	31/08/1996		Yes	No